Literature DB >> 15571641

Nebulizer use and maintenance by cystic fibrosis patients: a survey study.

Mary K Lester1, Patrick A Flume, Susan L Gray, Deborah Anderson, C Michael Bowman.   

Abstract

INTRODUCTION: Patients with cystic fibrosis (CF) suffer from chronic infection of the airways, and typical CF therapies include aerosolized medications. There is recent evidence that home nebulizers become contaminated by bacteria, causing concern that nebulizers may be a source of bacterial infection of the lower airways. A recent consensus document on infection-control issues for the CF population included recommendations on cleaning and disinfecting nebulizers.
METHODS: We surveyed 39 patients and their parents, as well as 54 respiratory therapists, regarding their routine nebulizer use and maintenance practices.
RESULTS: All the patients used at least one nebulized medication, and they used a variety of nebulizers, obtained from a wide variety of sources. Thirty percent of the patients used nebulizers well beyond the manufacturer's recommended replacement date. Ninety percent of the patients rinsed their nebulizers following use, but only 15% performed any routine disinfection. The respiratory therapists' nebulizer cleaning methods were widely disparate, with only 70% performing some method of rinsing. The respiratory therapists' self-report of cleaning methods and their instructions to patients regarding frequency of cleaning were so diverse that no standard is evident.
CONCLUSION: This study demonstrates that CF patients and their respiratory therapists should immediately address and improve their nebulizer cleaning methods and replacement practices. There should be more focus on teaching patients to regularly clean and replace nebulizers.

Entities:  

Mesh:

Year:  2004        PMID: 15571641

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  5 in total

1.  Preferences and Stated Adherence for Antibiotic Treatment of Cystic Fibrosis Pseudomonas Infections.

Authors:  Ateesha Farah Mohamed; F Reed Johnson; Maria-Magdalena Balp; Frederico Calado
Journal:  Patient       Date:  2016-02       Impact factor: 3.883

Review 2.  Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.

Authors:  David E Geller; Jeffry Weers; Silvia Heuerding
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2011-03-11       Impact factor: 2.849

Review 3.  Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence.

Authors:  Kamal Hamed; Laurie Debonnett
Journal:  Ther Adv Respir Dis       Date:  2017-02-17       Impact factor: 4.031

4.  Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.

Authors:  James Greenwood; Carsten Schwarz; Urte Sommerwerck; Edward F Nash; Michael Tamm; Weihua Cao; Paul Mastoridis; Laurie Debonnett; Kamal Hamed
Journal:  Ther Adv Respir Dis       Date:  2017-07       Impact factor: 4.031

5.  Effect that an educational program for cystic fibrosis patients and caregivers has on the contamination of home nebulizers.

Authors:  Adriana Della Zuana; Doroti de Oliveira Garcia; Regina Célia Turola Passos Juliani; Luiz Vicente Ribeiro Ferreira da Silva Filho
Journal:  J Bras Pneumol       Date:  2014 Mar-Apr       Impact factor: 2.624

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.